Fig. 6From: JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markersMedian change from baseline in a plasma MMP-7 concentration at week 4 versus CC-930 dose and b MMP-7 versus CC-930 exposure (AUC0−τ) predicted from the population pharmacokinetic model. a The dose was reduced from 100 mg BID to 100 mg QD within the first 4 weeks for one patient due to a protocol amendmentBack to article page